Australia’s medicinal cannabis industry continues to mature.
Domestic production has increased significantly in recent years. At the same time, imported product still accounts for the majority of supply. For compliant operators, this creates a dual opportunity: strengthen domestic supply while positioning facilities for regulated export.
As Regulatory Growth Consultants, HCPA helps organisations enter and scale highly regulated industries by using regulation as a growth advantage. In medicinal cannabis, the biggest opportunities do not exist in loosely structured or speculative models, they sit behind the regulated wall, where licensing, compliance and GMP alignment create sustainable scale.
Domestic Production Is Expanding Rapidly
Australia’s cultivation output has grown materially:
- Domestic production has increased from approximately 16–17 tonnes (2021) to over 40 tonnes.
- Licensed cultivation capacity continues to expand across multiple states.
- Investment in greenhouse and indoor facilities is increasing.
Australia now has meaningful cultivation output and infrastructure. The sector is transitioning from early-stage operators to larger, structured facilities built for compliance and long-term viability.
For operators considering entry, scale now depends less on enthusiasm and more on regulatory architecture, licence structure, security design, quality systems and supply chain alignment.
At HCPA, we work with cultivation and manufacturing businesses to structure facilities correctly from the outset, aligning Office of Drug Control (ODC) licensing, security protocols, GMP pathways and operational governance to support scalable growth.
Imports Still Supply the Majority of the Market
Despite domestic expansion:
- Imports exceeded 75 tonnes in 2024.
- More than 60% of total supply in recent years has been imported.
- Canada remains the primary international supplier.
This reliance on imported product highlights ongoing substitution opportunity for compliant domestic operators.
However, local production alone is not the differentiator. What determines long-term viability is regulatory precision ensuring cultivation, storage, prescribing pathways and distribution models are aligned with TGA, ODC and state-based requirements.
Practices that treat compliance as a secondary consideration often struggle to scale. In contrast, businesses that embed governance into their operating model are better positioned to capture both domestic demand and substitution growth.
Structured Facilities Enable Export and Multi-Product Supply
Export is permitted under ODC licences (with export permits), and GMP-aligned production enables access to regulated international markets.
When structured correctly, facilities can supply:
- Domestic wholesale markets
- Extraction and formulation pathways
- Regulated export markets
- Dried flower, extracts and finished products
This is where Regulatory Growth becomes tangible.
A compliant facility is not limited to domestic dried flower supply. With the correct licence scope, security design, post-harvest controls and GMP integration, operators can create multiple revenue pathways from a single structured asset.
As Regulatory Growth Consultants, HCPA supports operators to design their regulatory footprint early ensuring licensing, security systems, quality management and manufacturing pathways support future expansion rather than restrict it.
Case Study: Structured Growth in Practice
Recent industry examples demonstrate disciplined, compliance-led growth.
Eastern Highlands Cannabis (Queensland) launched commercial cultivation using a lean, low-capital polytunnel model targeting approximately 600kg initial production. Rather than pursuing rapid expansion, the founders prioritised structural efficiency, sponsor engagement and cost control, illustrating a measured domestic entry strategy aligned with regulatory discipline.
ECS Botanics has expanded beyond the local market, supplying Australian-grown medicinal cannabis into Europe, including the UK and Germany, following export approvals and GMP-aligned manufacturing integration.
These examples reinforce a consistent theme: scale follows structure.
Operators who align licensing, post-harvest systems, manufacturing integration and export permissions early create optionality. Those who treat compliance as an afterthought limit their pathways.
The Opportunity Sits Behind the Regulated Wall
Domestic demand continues to grow. Import substitution remains significant. Export markets are accessible.
But the advantage does not lie in speed alone.
It lies in regulatory structure.
In medicinal cannabis, the most durable growth occurs behind the regulated wall where governance, licence architecture, and compliance systems create access to approved supply chains, controlled markets and international pathways. This is what we define as Regulatory Growth: using regulation as a growth advantage rather than a limitation.
Looking Ahead
Australia’s medicinal cannabis sector is entering a more mature phase. Investment is becoming disciplined. Facilities are becoming structured. Export integration is becoming realistic for compliant operators.
For businesses considering entry or expansion, success will depend on:
- Appropriate ODC licensing strategy
- Security and facility compliance
- GMP alignment where required
- Structured domestic distribution pathways
- Export readiness built into early-stage design
Our vision is to open the world’s hardest industries to everybody by helping organisations navigate regulation with clarity and confidence.
In medicinal cannabis, those who build within the rules will be best positioned to scale responsibly across domestic and international markets.
How HCPA Supports Medicinal Cannabis Growth
HCPA is an all-in-one solution for medicinal cannabis operators.
As Regulatory Growth Consultants, we help businesses enter and scale highly regulated industries by turning regulation into a growth advantage aligning licensing, governance, facility design, and operational systems so growth is structured, compliant, and sustainable.
HCPA is an all-in-one solution for Medicinal Cannabis providers. We help businesses enter and scale highly regulated industries by turning regulation into a growth advantage. Contact us here or call 03 9084 7472 to learn how we can help you succeed.
